Cryo-Cell International,(CCEL) Inc. and its subsidiaries, a leading stem cell preservation company, released its unaudited financial statements for the second quarter of 2023. The report showcases the company's financial performance, highlighting net income and revenue figures for the quarter ended May 31, 2023.
During the second quarter of 2023, Cryo-Cell International reported a net income of $221,000. This positive financial result indicates the company's ability to generate profits despite various economic challenges and operational expenses.
The company's total revenue for the second quarter of 2023 amounted to $7.77 million. This figure includes processing and storage fees, public banking revenue, and product revenue. Cryo-Cell International's revenue stream demonstrated stability and growth during the reporting period. The financial statements also disclose the company's assets, liabilities, and stockholders' equity, giving investors and stakeholders a comprehensive view of Cryo-Cell International's financial health and stability.
Cryo-Cell International continues to play a significant role in the stem cell preservation industry, providing families with a valuable service to secure the future health of their loved ones. With a positive net income and robust revenue figures, the company is well-positioned to continue its mission and achieve further success in the coming quarters. Investors and stakeholders can look forward to continued financial stability and growth from this leading stem cell preservation company.
The financial data and statements provided above are unaudited and subject to change. Please refer to the company's official financial reports and disclosures for the most accurate and up-to-date information.